Asthma is a chronic inflammatory disease of the airways characterized by bronchial hyperreactivity and airway inflammation that increasingly afflicts the United States population. Individuals with severe asthma, suffer the most and drive at least 50% of the healthcare costs due to asthma in the U.S. To improve our understanding of this and other subgroups of this disease, the NHLBI initiated the Severe Asthma Research Program (SARP). This program identified 5 subgroups of asthma with different phenotypic features, of these, cluster 5 is characterized by severe irreversible airflow obstruction indicatin that airway remodeling is a key feature that discriminates the most severe subgroups of disease. Many of the molecular mechanisms that underlie airway remodeling have not been clearly elucidated in individuals with asthma. One of the main barriers to the characterization of airway remodeling has been the lack of safe access to the airway tissue itself in individuals with severe airflow impairment. In an effort to define novel pathways associated with the pathobiology of airway remodeling in asthma, our research team at the Yale Center for Asthma and Airways Disease (YCAAD) has developed a non-invasive protocol to measure genome-wide gene expression in the sputum of individuals with asthma. To identify regulatory genes that are associated with the development of airway remodeling and its relation with SARP clusters, we determined the effect of expression of microRNAs (miRNAs) on airflow obstruction in the YCAAD dataset. Analysis of miRNA expression in cells isolated from induced sputum with the Affymetrix 1.0 ST microarray identified an inverse correlation between hsa-miR-504 and baseline forced expiratory volume in 1 second (FEV1). In addition, hsa-miR-504 correlated positively with sputum levels of YKL-40, a chitinase-like protein we have previously shown to be associated with airway remodeling and increased asthma severity. A computational analysis overlapping the predicted hsa-miR-504 targets with the sputum gene expression profile, identified 90 transcripts that are likely to be hsa-miR-504 targets when a False Discovery Rate (FDR <0.05) threshold is used. Based on these exciting findings, we hypothesize that changes in the expression of hsa-miR-504 are indicative of asthma severity and that these changes lead to distinct changes in the expression of genes important in persistent inflammation and airway remodeling. To address this hypothesis we will focus on the following specific aims: 1). Determine the relationship between sputum hsa-miR-504, asthma and asthma severity. 2). Determine the cellular sources, immunophenotype and biologic targets of hsa-miR-504 in the sputum of individuals with asthma. 3). Identify a severe asthma phenotype associated with hsa-miR-504 and monitor its impact on adverse outcomes and changes in lung function through the longitudinal evaluation of subjects with asthma.

Public Health Relevance

Our research efforts will center on the impact of the microRNA 504 in asthma, in particular, severe disease. Severe asthma accounts for nearly $28 Billion dollars in healthcare expenses yearly. The ultimate goal is to identify novel therapies for severe asthma, targeting this specific microRNA and the genes it regulates.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Scientist Development Award - Research &amp; Training (K01)
Project #
1K01HL125474-01
Application #
8803630
Study Section
Special Emphasis Panel (ZHL1-CSR-F (O2))
Program Officer
Tigno, Xenia
Project Start
2014-11-15
Project End
2019-11-30
Budget Start
2014-11-15
Budget End
2015-11-30
Support Year
1
Fiscal Year
2015
Total Cost
$138,915
Indirect Cost
$10,290
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06510
Anathy, Vikas; Lahue, Karolyn G; Chapman, David G et al. (2018) Reducing protein oxidation reverses lung fibrosis. Nat Med 24:1128-1135
Sauler, Maor; Lamontagne, Maxime; Finnemore, Eric et al. (2018) The DNA repair transcriptome in severe COPD. Eur Respir J 52:
Nino, Cesar L; Perez, Geovanny F; Isaza, Natalia et al. (2018) Characterization of Sex-Based Dna Methylation Signatures in the Airways During Early Life. Sci Rep 8:5526
Gomez, Jose L; Kaminski, Naftali (2017) Toward Precision Medicine of Symptom Control in Asthma. Am J Respir Crit Care Med 195:147-148
Gomez, Jose L; Yan, Xiting; Holm, Carole T et al. (2017) Characterisation of asthma subgroups associated with circulating YKL-40 levels. Eur Respir J 50:
Yan, Xiting; Liang, Anqi; Gomez, Jose et al. (2017) A novel pathway-based distance score enhances assessment of disease heterogeneity in gene expression. BMC Bioinformatics 18:309
Rinne, Seppo T; Castaneda, Jose; Lindenauer, Peter K et al. (2017) Chronic Obstructive Pulmonary Disease Readmissions and Other Measures of Hospital Quality. Am J Respir Crit Care Med 196:47-55
Gutierrez, Maria J; Gomez, Jose L; Perez, Geovanny F et al. (2016) Airway Secretory microRNAome Changes during Rhinovirus Infection in Early Childhood. PLoS One 11:e0162244
Duncan, Gregg A; Lockett, Angelia; Villegas, Leah R et al. (2016) National Heart, Lung, and Blood Institute Workshop Summary: Enhancing Opportunities for Training and Retention of a Diverse Biomedical Workforce. Ann Am Thorac Soc 13:562-7